Can immune cells plus a checkpoint drug outsmart lymphoma?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Disease Specific Inclusion Criteria Group A (patients with measurable disease) Relapsed/Refractory Hodgkin Lymphoma (HL) and Diffuse Large B cell Lymphoma (DLBCL) DLBCL * Patients who have failed at least 2 lines of prior therapy with a failed attempt at both an autologous stem cell transplant and chimeric antigen receptor T cell therapy. * Patients who are deemed autologous stem cell transplant ineligible and have failed only one line of prior therapy. * Systemic therapies to treat prior indolent lymphomas count towards previous DLBCL lines of therapy unless the treatment was anti-CD20 antibody monotherapy. HL * Rel/ref HL failing more than or equal to 1 salvage regimens, including prior Brentuximab Vedotin (BV) * Rel/ref after autologous HSCT Group B (consolidation after auto-HSCT for patients at high risk for relapse) DLBCL * Patients with \< CMR/CR (by PET/CT) with initial treatment regimen * Patients with relapse \<12 months from diagnosis or \<6 months from completion of initial therapy * Patients with \<CMR/CR (by PET/CT) prior to autologous HSCT * Patients requiring \>1 salvage regimen prior to autologous HSCT HL * Patients with relapse \<12 months from diagnosis or \<6 months from completion of initial therapy * Patients with \<CMR/CR (by PET/CT) prior to autologous HSCT * Patients requiring \>1 salvage regimen prior to autologous HSCT Recipient Inclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell Generation): * Age \>12 years * Karnofsky/Lansky score of more than or equal to 50 (see appendix C). * ALC \> 600 * Patients receiving Granulocyte colony-stimulating factor (G-CSF) are recommended a washout period of a minimum of two weeks before procurement * Agree to use contraceptive measures during study protocol participation (when age appropriate) * Patient or parent/guardian capable of providing informed consent Recipient Exclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell Generation): * Prior allogeneic BMT * Prior solid organ transplant * Patient who has received ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment * Patient with uncontrolled infections * Patient with active HIV * Pregnancy or lactating * Failure to meet institutional guidelines for treatment with Nivolumab Recipient Inclusion Criteria for Initial and Subsequent TAA-T Cell Infusions: * Age \>12 years * Patient has received at least 8 weeks of Nivolumab * Patients with Grade 1 toxicities attributed to Nivolumab will be eligible at the discretion of the PI. Toxicities include but not limited to: laboratory abnormalities in thyroid function tests suggestive of hypothyroidism, thyroiditis or thyroid dysfunction adequately managed with thyroid hormone replacement, or abnormalities in amylase, lipase * Steroids less than 0.5 mg/kg/day prednisone or equivalent * Karnofsky/Lansky score of more than or equal to 50 * Pulse oximetry of \> 90% on room air * Bilirubin less than or equal to 2.5 mg/dL, AST/ALT less than or equal to 5x upper limit of normal, serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher) * Absolute neutrophil count \> 250/µL (may be supported with GCSF) * Agree to use contraceptive measures during study protocol participation (when age appropriate) * Patient or parent/guardian capable of providing informed consent Recipient Exclusion Criteria for Initial and Subsequent TAA-T Cell Infusions: * Investigational therapies within 28 days prior to screening for enrollment * Uncontrolled infections * Patient with ≥ grade 1 or symptomatic non-hematologic toxicities from prior therapies